First Eagle Investment Management LLC Makes New Investment in LifeMD, Inc. (NASDAQ:LFMD)

First Eagle Investment Management LLC acquired a new stake in LifeMD, Inc. (NASDAQ:LFMD) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 50,356 shares of the company’s stock, valued at approximately $249,000. First Eagle Investment Management LLC owned about 0.12% of LifeMD as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in LFMD. Connor Clark & Lunn Investment Management Ltd. raised its holdings in LifeMD by 21.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 931,294 shares of the company’s stock valued at $4,610,000 after buying an additional 165,378 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of LifeMD during the fourth quarter valued at about $473,000. Charles Schwab Investment Management Inc. raised its stake in shares of LifeMD by 5.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 108,478 shares of the company’s stock valued at $537,000 after acquiring an additional 6,034 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of LifeMD by 4.8% during the fourth quarter. Los Angeles Capital Management LLC now owns 127,435 shares of the company’s stock worth $631,000 after purchasing an additional 5,850 shares during the period. Finally, Rhumbline Advisers grew its stake in shares of LifeMD by 6.1% in the fourth quarter. Rhumbline Advisers now owns 48,689 shares of the company’s stock worth $241,000 after purchasing an additional 2,814 shares during the last quarter. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD Price Performance

NASDAQ:LFMD opened at $5.94 on Monday. The firm’s 50-day moving average price is $5.68 and its 200-day moving average price is $5.39. The company has a market capitalization of $264.83 million, a PE ratio of -9.28 and a beta of 1.50. LifeMD, Inc. has a 1-year low of $3.99 and a 1-year high of $12.88.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.02. The business had revenue of $64.26 million for the quarter, compared to the consensus estimate of $57.43 million. Equities analysts anticipate that LifeMD, Inc. will post -0.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on LFMD. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price target on shares of LifeMD in a research report on Tuesday, March 11th. Mizuho began coverage on shares of LifeMD in a report on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price target on the stock. KeyCorp decreased their price objective on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. HC Wainwright lifted their target price on shares of LifeMD from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, March 12th. Finally, Lake Street Capital initiated coverage on shares of LifeMD in a research report on Tuesday, December 10th. They set a “buy” rating and a $12.00 price target on the stock. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $11.43.

Insider Buying and Selling

In other LifeMD news, CEO Justin Schreiber sold 50,000 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $7.55, for a total value of $377,500.00. Following the sale, the chief executive officer now directly owns 2,653,715 shares of the company’s stock, valued at approximately $20,035,548.25. The trade was a 1.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 15.97% of the stock is currently owned by company insiders.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.